Insights from the dabigatran versus warfarin in patients with atrial fibrillation (RE-LY) trial

被引：8
|
作者：
Khoo, Chee W. [1 ]
Lip, Gregory Y. H. [1 ]
机构：
[1] Univ Birmingham, City Hosp, Ctr Cardiovasc Sci, Birmingham B18 7QH, W Midlands, England
来源：
EXPERT OPINION ON PHARMACOTHERAPY | 2010年 / 11卷 / 04期
关键词：
atrial fibrillation; dabigatran; direct thrombin inhibitor; stroke; DESIGN;
D O I：
10.1517/14656560903530691
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Oral anticoagulants such as warfarin have been used widely for the treatment of venous thromboembolism and stroke prevention in atrial fibrillation (AF) patients. Warfarin has significant limitations and also requires frequent monitoring. Thus, there is an unmet need, with the quest for alternative oral anticoagulants with stable pharmacokinetics and pharmacodynamics that do not need monitoring. The paper under evaluation provides us with up-to-date information on the safety and efficacy of a new oral anticoagulant, dabigatran, compared with warfarin for stroke prevention in AF patients.</.
引用
收藏
页码：685 / 687
页数：3
相关论文
共 50 条
  • [41] Urgent surgery or procedures in patients taking dabigatran or warfarin: Analysis of perioperative outcomes from the RE-LY trial
    Douketis, James D.
    Healey, Jeff S.
    Brueckmann, Martina
    Fraessdorf, Mandy
    Spyropoulos, Alex C.
    Wallentin, Lars
    Oldgren, Jonas
    Reilly, Paul
    Ezekowitz, Michael D.
    Connolly, Stuart J.
    Yusuf, Salim
    Eikelboom, John W.
    THROMBOSIS RESEARCH, 2016, 139 : 77 - 81
  • [42] Clinical outcomes of atrial fibrillation patients receiving NSAIDs in the RE-LY trial
    Ezekowitz, M. D.
    Connolly, S. J.
    Fraessdorf, M.
    Brueckmann, M.
    Kreuzer, J.
    Oldgren, J.
    Reilly, P.
    Yusuf, S.
    Wallentin, L.
    EUROPEAN HEART JOURNAL, 2015, 36 : 862 - 862
  • [43] Dabigatran versus Warfarin in Patients with Atrial Fibrillation
    Worthington, John M.
    Gattellari, Melina
    NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (27): : 2672 - 2673
  • [44] CLINICAL OUTCOMES OF ATRIAL FIBRILLATION PATIENTS RECEIVING DIGOXIN IN THE RE-LY® TRIAL
    Nagarakanti, Rangadham
    Connolly, Stuart
    Fraessdorf, Mandy
    Brueckmann, Martina
    Kreuzer, Joerg
    Reilly, Paul
    Oldgren, Jonas
    Yusuf, Salim
    Wallentin, Lars
    Ezekowitz, Michael
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 67 (13) : 802 - 802
  • [45] Anemia predicts thromboembolic events, bleeding complications and mortality in patients with atrial fibrillation: insights from the RE-LY trial
    Westenbrink, B. D.
    Alings, M.
    Connolly, S. J.
    Eikelboom, J.
    Ezekowitz, M. D.
    Oldgren, J.
    Yang, S.
    Pongue, J.
    Yusuf, S.
    Wallentin, L.
    van Gilst, W. H.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 (05) : 699 - 707
  • [46] Reasons for hospitalization and risk of mortality in patients with atrial fibrillation treated with dabigatran or warfarin in the Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) trial
    Alak, Aiman
    Hohnloser, Stefan H.
    Fraessdorf, Mandy
    Reilly, Paul
    Ezekowitz, Michael
    Healey, Jeff S.
    Brueckmann, Martina
    Yusuf, Salim
    Connolly, Stuart J.
    EUROPACE, 2019, 21 (07): : 1023 - 1038
  • [47] Risks for Stroke, Bleeding, and Death in Patients With Atrial Fibrillation Receiving Dabigatran or Warfarin in Relation to the CHADS2 Score: A Subgroup Analysis of the RE-LY Trial
    Oldgren, Jonas
    Alings, Marco
    Darius, Harald
    Diener, Hans-Christoph
    Eikelboom, John
    Ezekowitz, Michael D.
    Kamensky, Gabriel
    Reilly, Paul A.
    Yang, Sean
    Yusuf, Salim
    Wallentin, Lars
    Connolly, Stuart J.
    ANNALS OF INTERNAL MEDICINE, 2011, 155 (10) : 660 - +
  • [48] Review of the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial: Warfarin versus dabigatran
    Ingelmo C.
    Wazni O.
    Current Cardiology Reports, 2011, 13 (5) : 357 - 360
  • [49] Concomitant use of P-glycoprotein inhibitors with dabigatran or warfarin in the RE-LY trial
    Reilly, P. A.
    Connolly, S. J.
    Ezekowitz, M. D.
    Haertter, S.
    Noack, H.
    Wallentin, L.
    Yusuf, S.
    EUROPEAN HEART JOURNAL, 2011, 32 : 6 - 6
  • [50] Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial
    Wallentin, Lars
    Yusuf, Salim
    Ezekowitz, Michael D.
    Alings, Marco
    Flather, Marcus
    Franzosi, Maria Grazia
    Pais, Prem
    Dans, Antonio
    Eikelboom, John
    Oldgren, Jonas
    Pogue, Janice
    Reilly, Paul A.
    Yang, Sean
    Connolly, Stuart J.
    LANCET, 2010, 376 (9745): : 975 - 983
12345